Medical Device News Magazine

AI Model Proactively Predicts if a COVID-19 Test Might be Positive or Not

FAU Study Shows Machine-learning Models Trained Using Simple Symptoms, Demographic Features are Effective in Predicting COVID-19 Infections

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

COVID-19 and its latest Omicron strains continue to cause infections across the country as well as globally. Serology (blood) and molecular tests are the two most commonly used methods for rapid COVID-19 testing. Because COVID-19 tests use different mechanisms, they vary significantly. Molecular tests measure the presence of viral SARS-CoV-2 RNA while serology tests detect the presence of antibodies triggered by the SARS-CoV-2 virus.

Currently, there is no existing study on the correlation between serology and molecular tests and which COVID-19 symptoms play a key role in producing a positive test result. A study from Florida Atlantic University’s College of Engineering and Computer Science using machine learning provides important new evidence in understanding how molecular tests versus serology tests are correlated, and what features are the most useful in distinguishing between COVID-19 positive versus test outcomes.

Researchers from the College of Engineering and Computer Science trained five classification algorithms to predict COVID-19 test results. They created an accurate predictive model using easy-to-obtain symptom features, along with demographic features such as number of days post-symptom onset, fever, temperature, age and gender.

The study demonstrates that machine-learning models, trained using simple symptom and demographic features, can help predict COVID-19 infections. Results, published in the journal Smart Health, identify the key symptom features associated with COVID-19 infection and provide a way for rapid screening and cost effective infection detection.

Findings reveal that number of days experiencing symptoms such as fever and difficulty breathing play a large role in COVID-19 test results. Findings also show that molecular tests have much narrower post-symptom onset days (between three to eight days), compared to post-symptom onset days of serology tests (between five to 38 days). As a result, the molecular test has the lowest positive rate because it measures current infection.

Furthermore, COVID-19 tests vary significantly, partially because donors’ immune response and viral load – the target of different test methods – continuously change. Even for the same donor, it might be possible to observe different positive/negative results from two types of tests.

“Molecular tests depend on viral load and serology tests depend on seroconversion, which is the period during which the body starts producing detectable levels of antibodies. Both of these tests are time dependent,” said Xingquan “Hill” Zhu, Ph.D., senior author and a professor in FAU’s Department of Electrical Engineering and Computer Science. “Our results suggest that the number of days post symptomatic are highly important for a positive COVID-19 test and should be under careful consideration when screening patients.”

For the study, researchers used test results from 2,467 donors, each tested using one or multiple types of COVID-19 tests, which were collected as the testbed. They combined symptoms and demographic information to design a set of features for predictive modeling using the five types of machine-learning models. By cross checking test types and results, they examined the correlation between serology and molecular tests. For test outcome prediction, they labeled the 2,467 donors as positive or negative by using their serology or molecular test results, and created symptom features to represent each donor for machine learning.

“Because COVID-19 produces a wide range of symptoms and the data collection process is essentially error prone, we grouped similar symptoms into bins,” said Zhu. “Without a standardization of symptom reporting, the symptom feature space greatly increases. To combat this, we utilized this binning approach, which was able to decrease symptom feature space while keeping sample feature information.”

By using created bin features, combined with the five machine-learning algorithms, these predictive models achieved more than 81 percent AUC scores (Area under the ROC Curve, which provides an aggregate measure of performance across all possible classification thresholds), and more than 76 percent classification accuracy.

“One unique feature of our testbed is that some donors may have multiple test results, which allowed us to analyze the relationship between serology tests versus molecular tests, and also understand consistency within each type of test,” said Zhu.

The five machine learning models used by the researchers are Random Forest, XGBoost, Logistic Regression, Support Vector Machine (SVM) and Neural Network. They compared performance by using three performance metrics: Accuracy, F1-score and AUC.

“Predictive modeling is complicated by many puzzling questions unanswered by research. The testbed created by our researchers is indeed novel and clearly shows correlation between different types of COVID-19 tests,” said Stella Batalama, Ph.D., dean, FAU College of Engineering and Computer Science. “Our researchers have designed a new way to narrow down noisy symptom features for clinical interpretation and predictive modeling. Such AI based predictive modeling approaches are becoming increasingly powerful to combat infectious diseases and many other aspects of health issues.”

Study co-author is Magdalyn E. Elkin, a Ph.D. student in FAU’s Department of Electrical Engineering and Computer Science.

This work was supported by the National Science Foundation.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”